Merck's Keytruda Obtains its First FDA Approval for Mesothelioma

Merck & Co., Inc. (MRK) announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication.The regulatory body has now approved Keytruda in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). Pleural mesothelioma is a type of cancer which develops in the tissue that lines the lungs or pleura.This is the first time Keytruda has been ...